J Clin Neurol.  2017 Oct;13(4):432-434. 10.3988/jcn.2017.13.4.432.

Anaphylaxis after Idarucizumab Infusion

• Nam KW
• Choo I
• Chang JY
• Jung S
• Kim BJ
• Han MK
• Bae HJ

• KMID: 2392143
• DOI: http://doi.org/10.3988/jcn.2017.13.4.432

Abstract

No abstract available.

MeSH Terms

Anaphylaxis*

Figure

• 

  Fig. 1 Brain and skin lesions after the anaphylactic event. A: Initial brain CT. B: Diffusion weighted imaging showed a hemorrhage with multiple fluid levels in the right temporo-parietal area. C and D: A skin rash developed on the trunk and both upper limbs immediately after the infusion of idarucizumab.

Reference

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151.

2. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012; 43:1511–1517.

3. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373:511–520.

4. Pollack CV Jr, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015; 114:198–205.

5. Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13:725–732.

6. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med. 2006; 47:373–380.